<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04107571</url>
  </required_header>
  <id_info>
    <org_study_id>20190924</org_study_id>
    <nct_id>NCT04107571</nct_id>
  </id_info>
  <brief_title>A Registry Study on Serumal Biomarkers About Adverse Events in Patients Undergoing Coronary Artery Bypass Grafting.</brief_title>
  <acronym>ASBA-CABG</acronym>
  <official_title>A Chinese Registry to Determine the Serumal Biomarkers for Prognosis of Adverse Events in Patients Undergoing Coronary Artery Bypass Grafting.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Institute of Heart, Lung and Blood Vessel Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Institute of Heart, Lung and Blood Vessel Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a national registry study to determine the serumal biomarkers for prognosis of
      adverse events in patients undergoing coronary artery bypass grafting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause death and cardiac death</measure>
    <time_frame>These data is collected during follow-up visit at in-hospital/1 year after discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE)</measure>
    <time_frame>These data is collected during follow-up visit at in-hospital/1 year after discharge</time_frame>
    <description>A composite of death, myocardial infarction, stroke, heart failure, ventricular arrhythmia</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>A type of operation for coranary heart disease patients.</intervention_name>
    <description>A type of operation for coranary heart disease patients.</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      If a blood specimen is obtained, it will be separated and stored at -80 â„ƒ as plasma, viable
      cells, and extracted DNA. If a saliva specimen is obtained, it is stored for DNA.

      If a tissue specimen is obtained, it will be cut into small pieces and stored at liquid
      nitrogen.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Group consists of patients who underwent coronary artery bypass grafting in Beijing Anzhen
        Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject undergoing coronary artery bypass grafting;

          2. Age is more than 18 and less than 80 years old;

          3. Male and non pregnancy female;

          4. Subject who understands study requirements and agrees to sign an informed consent from
             prior to study procedures.

        Exclusion Criteria:

          1. Pregnancy female;

          2. Participate in other clinical trial in the last 1 month.

          3. Subject who doesn't agree to sign an informed consent from prior to study procedures.

          4. Subject undergoing repeat CABG, concomitant valve or other cardiac surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Du, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yulin Li, PHD</last_name>
    <phone>86-010-64426153</phone>
    <email>lyllyl_1111@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Du, PHD</last_name>
    <email>jiedubj@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ke-xu Yang</last_name>
      <phone>86-010-64426153</phone>
      <email>EC@anzhenGCP.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary artery bypass graft</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Prognosis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

